Use the tables and source links to compare options, then confirm the details with the clinic or supplier. For personal medical decisions, use a licensed UAE clinician.
The short version
KLOW is not a single standard peptide name. In the current Nova BioLabs listing, KLOW Blend is an 80mg supplier-named research blend containing GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg. In the UAE directory, Nova BioLabs and SHLABZ currently have KLOW research-supplier listings. No clinic in the current directory directly names KLOW, although several Dubai clinics mention overlapping components such as BPC-157, GHK-Cu and TB-500 or thymosin beta-4.
A study about a molecule is not the same as proof that a specific clinic service or supplier product is approved, correctly made, or suitable for you.
Current KLOW Blend supplier listings
These are the KLOW Blend listings currently tracked in the public product directory. Compare the full product page before assuming two KLOW listings have the same composition, format or source documentation.
| Product | Supplier | Format | Price | Status |
|---|---|---|---|---|
| KLOW Blend80MG | Nova BioLabs | vial | AED 560 | In stock |
| KLOW Blend Pen80MG | Nova BioLabs | pen | AED 890 | In stock |
| KLOW Blend80 MG | SHLABZ | vial | AED 900 | In stock |
What KLOW Blend is
KLOW is best understood as a brand or supplier blend name, not as a single peptide molecule. That distinction matters because two suppliers could use the same blend name while changing the ingredient mix, strength or format.
The current Nova BioLabs KLOW Blend product page describes an 80mg blend made from GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg. The product directory snapshot also records Nova KLOW vial and KLOW pen listings, plus a SHLABZ KLOW vial listing.
Because KLOW combines several experimental research compounds, do not evaluate it only by the name on the label. The useful comparison is the full ingredient list, total strength, supplier, format, testing documentation, stock status and current source page.
Research use-case categories
Supplier pages tend to position KLOW around skin, connective-tissue, recovery and inflammatory-signalling research. Those are research themes, not proof that the blend is an established treatment.
GHK-Cu is usually the reason KLOW appears in skin and beauty searches. BPC-157 and TB-500 are usually the reason it appears in recovery or connective-tissue searches. KPV is usually discussed around inflammatory and immune-signalling models.
The practical point for readers is that KLOW sits across several search intents at once: skin appearance, repair/recovery, inflammation-related research and peptide blends. That makes it easy for marketing language to sound broader than the actual evidence. Treat each component separately before accepting a claim about the blend as a whole.
- Skin and cosmetic-adjacent research: mainly GHK-Cu-related searches.
- Recovery and connective-tissue research: mainly BPC-157 and TB-500-related searches.
- Inflammatory-signalling research: mainly KPV-related searches.
- Blend comparison: check whether the listing is KLOW specifically or just a BPC/TB, GHK-Cu or KPV product.
Which research suppliers currently list KLOW in the UAE directory
The current public supplier snapshot records two visible suppliers with KLOW listings. Nova BioLabs lists KLOW Blend vial at AED 560 and KLOW Blend Pen at AED 890. SHLABZ lists KLOW Blend vial at AED 899.99.
BodyPharm UAE does not currently have a direct KLOW match in the public snapshot. It may still list related individual compounds or other blends, but that is not the same as a KLOW listing.
Prices and stock labels are supplier-provided catalogue data. They should be checked on the supplier source page before relying on them, especially because blend products can change format, strength or availability.
Which UAE clinics mention KLOW or its components
No clinic in the current directory directly names KLOW Blend. That is important: a clinic mentioning BPC-157, GHK-Cu or TB-500 does not mean the clinic offers KLOW as a finished blend.
Several Dubai clinic profiles do mention overlapping components. DNA Health & Wellness lists BPC-157, thymosin beta-4 and GHK-Cu among clinic-stated offerings. Dynamic Life Clinics lists BPC-157, GHK-Cu and thymosin beta-4 and publishes public price signals for those categories. Enfield Royal Clinic lists BPC-157, GHK-Cu and TB-500. MedPalm Poly Clinic lists BPC-157, GHK-Cu and thymosin beta-4. The Nova Clinic lists BPC-157 and TB-500.
The current clinic data does not record a KPV clinic mention. If a clinic says it can provide KLOW or a similar blend, ask for the exact finished product, ingredient list, legal clinical basis and whether the product is registered for the proposed use.
Approval status and evidence limits
KLOW Blend should be treated as experimental unless a provider identifies an approved finished product and a valid UAE clinical basis for the proposed use. A research-supplier listing is not the same thing as a registered medicine or a licensed clinic treatment.
The evidence question is also layered. Individual components such as GHK-Cu, BPC-157, TB-500 and KPV have different research histories, but that does not automatically validate a combined KLOW blend. A multi-compound blend needs evidence for the exact composition and intended use, not only separate references for each ingredient.
For consumer searches, the safest way to think about KLOW is as a research-catalogue blend with overlapping skin, recovery and inflammatory-signalling themes. It should not be treated as a proven clinical shortcut.
Questions to ask before comparing KLOW options
Use these questions to separate a useful listing from vague marketing. They apply whether you are looking at a supplier catalogue or asking a clinic about a similar blend.
- Is the product actually named KLOW, or is it a different blend using some of the same components?
- What are the exact ingredients and strengths for GHK-Cu, BPC-157, TB-500 and KPV?
- Is the listing a vial, pen or another format?
- Does the supplier publish batch-level testing or only general testing claims?
- If a clinic mentions it, is there a registered finished product for the proposed clinical use?
- Is the claim based on human clinical evidence for the full blend, or mainly separate preclinical evidence for individual ingredients?
- What is included in any clinic quote: consultation, product, monitoring, follow-up and VAT?
Frequently asked questions
Is this page medical advice?
No. It is general information to help you ask better questions. A licensed UAE healthcare professional should assess your own symptoms, risks, medicines and treatment options.
Does appearing online mean a peptide is approved in the UAE?
No. A website, social-media post or UAE delivery option does not prove that a product is registered, legal to import, or approved for human use.
What is KLOW Blend?
KLOW is a supplier-named blend, not a single peptide. Nova BioLabs currently describes its KLOW Blend as GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg.
Which UAE suppliers currently list KLOW?
The current public directory snapshot shows KLOW listings from Nova BioLabs and SHLABZ. Nova lists a vial and pen; SHLABZ lists a vial. BodyPharm does not currently have a direct KLOW match in the public snapshot.
Which UAE clinics offer KLOW?
No clinic in the current directory directly names KLOW Blend. Some Dubai clinics mention overlapping components such as BPC-157, GHK-Cu and TB-500 or thymosin beta-4, but that does not mean they offer KLOW as a finished blend.
What is KLOW usually researched for?
Supplier positioning usually connects KLOW to skin, connective-tissue, recovery and inflammatory-signalling research themes. Those themes come from the components in the blend and should not be treated as established clinical outcomes.
Is KLOW approved for human use in the UAE?
Do not assume approval. This site treats KLOW Blend as not approved for human use unless a provider can identify an approved finished product and the legal clinical basis for the proposed use.
Sources and further reading
We check for clear status labels, cited sources, and unsupported health claims. Named clinical expert review will be shown when available.